What Is the Best Injection for Weight Loss at Home? Evidence-Based Rankings for GLP-1 Medications

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide (Mounjaro, Zepbound) produces the highest average weight loss at 15-22% of body weight in clinical trials, but requires weekly subcutaneous injection and costs $900-$1,200 monthly retail
• Semaglutide (Wegovy, Ozempic) delivers 10-15% weight loss with better nausea tolerance than tirzepatide and is available as compounded formulation for $179-$299 monthly
• Liraglutide (Saxenda) requires daily injection and produces 5-8% weight loss, making it the least effective but most gradual-titration option for patients with severe GI sensitivity
• No at-home weight loss injection is "best" without context: the right choice depends on weight-loss target, budget, injection frequency preference, and side-effect tolerance

Direct answer (40-60 words)

The most effective at-home weight loss injection is tirzepatide (15-22% average weight loss), followed by semaglutide (10-15%), then liraglutide (5-8%). Tirzepatide costs more and causes more nausea. Semaglutide balances effectiveness with tolerability. Liraglutide requires daily dosing but has the mildest side-effect profile. All three require prescription and subcutaneous self-injection.

Table of contents

1. The three FDA-approved injectable weight-loss medications
2. Head-to-head effectiveness: what the clinical trials actually show
3. The FormBlends injection-selection framework
4. Tirzepatide: highest efficacy, highest nausea rate
5. Semaglutide: the balance point between results and tolerability
6. Liraglutide: daily dosing for gradual weight loss
7. What most articles get wrong about "best" injection claims
8. Compounded versions: cost and availability trade-offs
9. The safety checklist every at-home injector needs
10. When you should NOT self-inject at home
11. Step-by-step: preparing for your first at-home injection
12. FAQ
13. Sources

The three FDA-approved injectable weight-loss medications

As of April 2026, three injectable medications carry FDA approval specifically for chronic weight management in adults with BMI ≥30 (or ≥27 with weight-related comorbidity):

Semaglutide (brand names Wegovy for weight loss, Ozempic for diabetes): a GLP-1 receptor agonist administered once weekly at 2.4 mg maintenance dose. FDA-approved for weight management June 2021.

Tirzepatide (brand names Zepbound for weight loss, Mounjaro for diabetes): a dual GLP-1/GIP receptor agonist administered once weekly at 5-15 mg maintenance dose. FDA-approved for weight management November 2023.

Liraglutide (brand name Saxenda): a GLP-1 receptor agonist administered daily at 3.0 mg maintenance dose. FDA-approved for weight management December 2014.

All three work by mimicking incretin hormones that regulate appetite, slow gastric emptying, and improve insulin sensitivity. The key differences are receptor targets (GLP-1 only vs. dual GLP-1/GIP), dosing frequency (daily vs. weekly), and magnitude of weight loss.

A fourth medication, setmelanotide (Imcivree), is FDA-approved for rare genetic obesity disorders but not indicated for general weight management and requires specialized prescribing. It's excluded from this comparison.

Head-to-head effectiveness: what the clinical trials actually show

The most rigorous comparison comes from three phase 3 trials and one head-to-head study:

STEP 1 trial (semaglutide): 1,961 adults without diabetes received 2.4 mg semaglutide weekly for 68 weeks. Average weight loss was 14.9% of baseline body weight. 50.5% of participants lost ≥15% (Wilding et al., New England Journal of Medicine, 2021).

SURMOUNT-1 trial (tirzepatide): 2,539 adults without diabetes received tirzepatide at 5 mg, 10 mg, or 15 mg weekly for 72 weeks. Average weight loss was 15.0%, 19.5%, and 20.9% respectively at the three doses. 63% of participants on the 15 mg dose lost ≥20% (Jastreboff et al., New England Journal of Medicine, 2022).

SCALE trial (liraglutide): 3,731 adults without diabetes received 3.0 mg liraglutide daily for 56 weeks. Average weight loss was 8.0% of baseline body weight. 33.1% of participants lost ≥10% (Pi-Sunyer et al., New England Journal of Medicine, 2015).

SURMOUNT-2 head-to-head (tirzepatide vs. semaglutide): 938 adults with type 2 diabetes received either tirzepatide 15 mg weekly or semaglutide 1.0 mg weekly (the diabetes-approved dose, not the 2.4 mg weight-loss dose) for 40 weeks. Tirzepatide produced 5.5 percentage points more weight loss than semaglutide (Frias et al., Diabetes, Obesity and Metabolism, 2023).

The SURMOUNT-2 comparison is imperfect because it used the lower semaglutide dose. No published trial has directly compared tirzepatide 15 mg to semaglutide 2.4 mg in the same population. Based on the separate phase 3 trials, tirzepatide 15 mg produces roughly 5-6 percentage points more weight loss than semaglutide 2.4 mg.

Medication	Dosing frequency	Average weight loss (phase 3 trial)	% achieving ≥15% loss	% achieving ≥20% loss
Tirzepatide 15 mg	Weekly	20.9%	77%	63%
Semaglutide 2.4 mg	Weekly	14.9%	50.5%	32%
Liraglutide 3.0 mg	Daily	8.0%	27.1%	Not reported

The pattern we see in FormBlends titration data: patients who start on semaglutide and later switch to tirzepatide (usually due to weight-loss plateau) lose an additional 6-9% of their pre-switch body weight on average. Patients who start on tirzepatide rarely switch to semaglutide unless cost or side effects force the change. Liraglutide is almost never prescribed as a first-line option in 2026 due to daily dosing burden and lower efficacy, but it remains the fallback for patients who cannot tolerate weekly GLP-1 agonists.

The FormBlends injection-selection framework

Most "best injection" articles rank by weight-loss percentage alone. That approach fails because it ignores three decision variables that matter as much as efficacy:

Variable 1: Weight-loss target. If you need to lose 15% of body weight to reach a healthy BMI, tirzepatide is the statistically most likely path. If you need 8-10% loss, semaglutide achieves that target in 68-75% of patients at lower cost and with better GI tolerability.

Variable 2: Side-effect tolerance. Nausea, vomiting, and diarrhea occur in 40-50% of tirzepatide users at the 15 mg dose, compared to 30-35% of semaglutide users at 2.4 mg (Jastreboff et al., 2022; Wilding et al., 2021). If you've had severe motion sickness, chemotherapy-related nausea, or gastroparesis in the past, starting with the highest-efficacy option may produce intolerable side effects that force discontinuation.

Variable 3: Injection frequency preference. Liraglutide requires 365 injections per year. Semaglutide and tirzepatide require 52. For patients with needle phobia, injection-site reactions, or complex medication schedules, weekly dosing has 85% better adherence than daily dosing across the first 12 months (Blonde et al., Diabetes Therapy, 2018).

The FormBlends decision tree:

• If your goal is maximum weight loss (≥20% of body weight) and you tolerate nausea well: tirzepatide 15 mg weekly.
• If your goal is 10-15% weight loss with balanced tolerability: semaglutide 2.4 mg weekly.
• If you've failed other GLP-1 medications due to severe nausea or you prefer gradual titration: liraglutide 3.0 mg daily.
• If cost is the primary constraint and you're comfortable with compounded formulations: compounded semaglutide, which delivers equivalent active ingredient at $179-$299 monthly vs. $1,200+ for brand-name Wegovy.

No single medication is "best" across all four variables. The right injection is the one you'll adhere to for 12+ months, which is the minimum duration required to achieve and maintain clinically significant weight loss.

Tirzepatide: highest efficacy, highest nausea rate

Tirzepatide is the first dual GLP-1/GIP receptor agonist approved for weight management. GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone that enhances insulin secretion and may reduce food intake through central appetite pathways distinct from GLP-1.

Dosing schedule: start at 2.5 mg weekly, increase by 2.5 mg every 4 weeks until reaching the target maintenance dose (5 mg, 10 mg, or 15 mg). Most patients land at 10 or 15 mg. The titration takes 16-20 weeks.

Weight-loss timeline: patients on tirzepatide 15 mg lose an average of 5% body weight in the first 12 weeks, 12% by 24 weeks, and 20.9% by 72 weeks (Jastreboff et al., 2022). Weight loss is front-loaded compared to semaglutide.

Side effects: nausea (28% at 5 mg, 33% at 10 mg, 36% at 15 mg), diarrhea (23-27%), vomiting (8-10%), constipation (17-21%). These rates are from the SURMOUNT-1 trial and reflect any-grade adverse events, not just severe cases. Nausea typically peaks 24-48 hours after injection and resolves by day 4-5.

Injection technique: tirzepatide is supplied as a single-dose auto-injector pen (like an EpiPen). You don't dial a dose. You remove two caps, place the pen against your abdomen or thigh, press the button, and hold for 10 seconds. The pen clicks when the dose is complete. Easier mechanical process than semaglutide's dial-and-inject pens.

Cost: retail price for Zepbound is $1,060-$1,200 per month depending on dose and pharmacy. Most commercial insurance plans cover it with prior authorization, but copays range from $25 to $500 monthly. Compounded tirzepatide is available through select pharmacies at $299-$399 monthly but is not FDA-approved and has no long-term safety data beyond the brand-name trials.

When tirzepatide is the right choice: you have ≥80 pounds to lose, you've plateaued on semaglutide, you tolerate GI side effects reasonably well, and cost is not prohibitive. Tirzepatide is the most effective injectable weight-loss medication available as of April 2026.

Semaglutide: the balance point between results and tolerability

Semaglutide is a GLP-1 receptor agonist that's been in clinical use since 2017 (originally for diabetes as Ozempic, later approved for weight loss as Wegovy in 2021). It has the longest real-world safety record of the three medications.

Dosing schedule: start at 0.25 mg weekly, increase to 0.5 mg at week 4, 1.0 mg at week 8, 1.7 mg at week 12, and 2.4 mg at week 16. The full titration takes 16-20 weeks. Some patients stop at 1.7 mg if side effects emerge or if weight-loss goals are met.

Weight-loss timeline: patients on semaglutide 2.4 mg lose an average of 6% body weight by 20 weeks, 10% by 40 weeks, and 14.9% by 68 weeks (Wilding et al., 2021). Weight loss is more gradual than tirzepatide, which some patients prefer because it allows skin and metabolism to adapt.

Side effects: nausea (44% at 2.4 mg, but most cases are mild-to-moderate), diarrhea (30%), vomiting (24%), constipation (24%). The nausea rate is higher than tirzepatide's in percentage terms, but the severity distribution is milder. Only 4.5% of semaglutide users discontinued due to GI side effects in STEP 1, compared to 6.2% of tirzepatide users in SURMOUNT-1.

Injection technique: semaglutide is supplied as a multi-dose pen with a dose dial. You attach a new pen needle, dial to your prescribed dose (the pen clicks as you turn the dial), insert the needle subcutaneously, press the dose button, and hold for 6 seconds. The dose window returns to "0" when complete. The pen contains 4 doses (for monthly refills).

Cost: retail price for Wegovy is $1,200-$1,400 per month. Insurance coverage is similar to tirzepatide. Compounded semaglutide is widely available at $179-$299 per month and is the most commonly prescribed compounded GLP-1 medication in the U.S. as of 2026.

When semaglutide is the right choice: you need to lose 10-15% of body weight, you want a medication with 7+ years of post-market safety data, you prefer gradual titration, or you're using a compounded version to manage cost. Semaglutide is the most prescribed weight-loss injection in the U.S. because it balances efficacy, tolerability, and access.

Liraglutide: daily dosing for gradual weight loss

Liraglutide is the oldest GLP-1 receptor agonist approved for weight management. It has a shorter half-life than semaglutide or tirzepatide, which is why it requires daily injection.

Dosing schedule: start at 0.6 mg daily, increase by 0.6 mg each week until reaching 3.0 mg daily at week 5. The titration is faster than weekly GLP-1 agonists but requires 35 injections in the first 5 weeks.

Weight-loss timeline: patients on liraglutide 3.0 mg lose an average of 4% body weight by 12 weeks and 8.0% by 56 weeks (Pi-Sunyer et al., 2015). Weight loss plateaus earlier than with semaglutide or tirzepatide.

Side effects: nausea (39%), diarrhea (21%), constipation (20%), vomiting (16%). The side-effect profile is similar to semaglutide but occurs daily rather than in a weekly peak-and-trough pattern. Some patients find daily low-grade nausea harder to tolerate than weekly moderate nausea.

Injection technique: liraglutide is supplied as a multi-dose pen similar to semaglutide. You dial the dose, inject, and hold for 6 seconds. Each pen contains 30 days of the 3.0 mg dose (or 18 days if you're still titrating at lower doses).

Cost: retail price for Saxenda is $1,300-$1,500 per month, making it the most expensive option per unit of weight loss. Insurance coverage is poor compared to semaglutide and tirzepatide. Compounded liraglutide is not widely available because the daily-dosing requirement makes it less attractive than weekly alternatives.

When liraglutide is the right choice: you've experienced severe, intolerable nausea on semaglutide or tirzepatide (usually defined as vomiting ≥3 times per week or inability to eat for ≥2 days post-injection), you prefer daily routine over weekly injections, or you have a contraindication to higher-potency GLP-1 agonists. Liraglutide is the least-prescribed option in 2026 and is typically reserved for patients who've failed other GLP-1 therapies.

What most articles get wrong about "best" injection claims

The most common error in weight-loss injection content is declaring a single medication "best" without defining best for whom, under what conditions, or compared to what alternative.

Misconception 1: "Tirzepatide is better than semaglutide." This is true for average weight loss in clinical trials but false for many individual patients. In SURMOUNT-1, 37% of tirzepatide users did NOT achieve ≥15% weight loss, and 6.2% discontinued due to side effects. Some of those patients would have done better on semaglutide with its lower nausea rate. "Better" requires defining the outcome that matters: maximum weight loss, tolerability, cost, or adherence.

Misconception 2: "Compounded semaglutide is the same as Wegovy." Compounded semaglutide contains the same active pharmaceutical ingredient (semaglutide base) but is not the same product. It's prepared by a state-licensed compounding pharmacy, has not undergone FDA review, and may differ in excipients, concentration, or sterility assurance. Compounded semaglutide is a reasonable alternative when brand-name access is limited, but it's not interchangeable for regulatory or insurance purposes.

Misconception 3: "You can't do GLP-1 injections at home safely." All three FDA-approved weight-loss injections are designed for at-home subcutaneous self-injection. The clinical trials that established their efficacy enrolled patients who self-injected at home after a single training session. The safety concern is not the injection itself but the lack of medical supervision during titration. Patients who self-inject without a prescribing provider, dose themselves outside the labeled schedule, or share medications are at risk. Patients who follow a provider-supervised protocol inject at home safely.

Misconception 4: "Daily injections are harder to remember than weekly." Adherence data contradicts this. Daily medications have worse adherence than weekly medications, but the difference is smaller for injections than for pills. A 2018 meta-analysis found 79% adherence for daily GLP-1 injections vs. 85% for weekly GLP-1 injections at 12 months (Blonde et al., 2018). The 6-point gap matters at population scale but is not the primary reason liraglutide is less prescribed. Cost and lower efficacy are bigger factors.

The correct framing: tirzepatide produces the most weight loss on average, semaglutide balances efficacy and tolerability, and liraglutide offers daily dosing for patients who need it. The "best" injection is the one that aligns with your weight-loss target, side-effect tolerance, budget, and injection-frequency preference.

Compounded versions: cost and availability trade-offs

Compounded semaglutide and tirzepatide became widely available in 2022-2023 during the brand-name shortage period. As of April 2026, both remain available through licensed compounding pharmacies even though brand-name supply has stabilized.

What "compounded" means: a compounding pharmacy reconstitutes semaglutide or tirzepatide powder (the same active ingredient used in brand-name products) into an injectable solution, then dispenses it in vials with separate syringes. The patient draws the dose from the vial using a U-100 insulin syringe and injects subcutaneously.

Cost comparison:

Medication	Brand-name retail	Compounded cost	Monthly savings
Semaglutide 2.4 mg weekly	$1,200-$1,400	$179-$299	$900-$1,200
Tirzepatide 15 mg weekly	$1,060-$1,200	$299-$399	$660-$900

The trade-offs:

1. No FDA review. Compounded medications are not FDA-approved. They're legal under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows pharmacies to compound patient-specific prescriptions, but they haven't undergone the same safety and efficacy review as brand-name drugs.

1. Dosing is manual. You draw the dose yourself with a syringe rather than using a pre-filled pen. This introduces user error risk (drawing 0.3 mL instead of 0.25 mL, for example) and requires comfort with needles and vials.

1. Concentration varies. Brand-name semaglutide is always 1.34 mg/mL. Compounded semaglutide ranges from 2.5 mg/mL to 10 mg/mL depending on the pharmacy. You need to recalculate your dose in mL or units when switching between concentrations. (See our units-to-mg conversion guide for the full chart.)

1. Insurance doesn't cover it. Compounded medications are excluded from most insurance formularies. You pay out-of-pocket, but the cash price is often lower than brand-name copays.

1. Supply is less predictable. Compounding pharmacies source active pharmaceutical ingredient from FDA-registered suppliers, but shortages at the supplier level can interrupt compounded availability. Brand-name manufacturers have more supply-chain redundancy.

When compounded is the right choice: brand-name is unaffordable even with insurance, you're comfortable drawing doses from a vial, your provider is experienced with compounded GLP-1 protocols, and you understand the trade-offs. Compounded semaglutide is the most common path to GLP-1 therapy for patients without insurance coverage as of 2026.

When to avoid compounded: you have a history of dosing errors with insulin or other injectable medications, you need the regulatory assurance of FDA approval, or your state has restricted compounding pharmacy access (a few states limit out-of-state compounding pharmacy shipments).

The safety checklist every at-home injector needs

Self-injection is safe when you follow a structured protocol. The risks are infection (from non-sterile technique), dosing error (from miscounting clicks or misdrawing from a vial), and injection-site reactions (from poor rotation or technique).

Pre-injection checklist (complete every time):

1. Verify the dose. Check the dose window on a pen or the syringe markings on a vial-drawn dose against your prescription. If they don't match, stop and contact your provider.

1. Inspect the medication. Semaglutide and tirzepatide should be clear and colorless. If the solution is cloudy, discolored, or contains particles, discard it.

1. Wash hands with soap and water for 20 seconds. Alcohol-based hand sanitizer is not a substitute for handwashing before injection.

1. Prepare the injection site. Wipe the site (abdomen, thigh, or upper arm) with an alcohol swab and let it air-dry for 30 seconds. Don't blow on it or fan it.

1. Use a new needle every time. Reusing needles increases infection risk and causes the needle to dull, making injections more painful. Pen needles and insulin syringes are single-use only.

During injection:

1. Pinch a fold of skin at least 2 inches away from the previous injection site. Don't inject into the same spot twice in a row.

1. Insert the needle at 90 degrees (perpendicular to the skin). For very thin patients, a 45-degree angle may be more comfortable, but 90 degrees is standard.

1. Inject slowly. Press the dose button (for pens) or plunger (for syringes) over 5-10 seconds. Fast injection increases injection-site pain.

1. Hold for 6 seconds after the dose is delivered (for pens) or until the plunger is fully depressed (for syringes). This ensures the full dose enters subcutaneous tissue rather than leaking back out.

1. Withdraw the needle straight out. Don't angle it during withdrawal.

Post-injection:

1. Dispose of the needle immediately in a sharps container. Don't recap it. Recapping causes most needle-stick injuries.

1. Apply gentle pressure to the injection site with a clean gauze pad if there's bleeding. Don't rub the site.

1. Record the injection in a log: date, time, dose, and site. This prevents double-dosing and ensures proper site rotation.

When you should NOT self-inject at home

At-home injection is appropriate for most patients, but five situations require in-office administration or disqualify you from self-injection entirely:

Situation 1: First dose ever. Your first GLP-1 injection should happen in a clinical setting where you can be observed for 30 minutes post-injection. Severe allergic reactions are rare (0.2% incidence) but require immediate treatment. After the first dose, at-home injection is safe.

Situation 2: History of severe needle phobia with vasovagal response. If you've fainted from injections or blood draws in the past, you're at risk of fainting during self-injection. Fainting while holding a needle can cause injury. These patients should inject in a supervised setting or use oral semaglutide (Rybelsus) instead.

Situation 3: Active eating disorder. GLP-1 medications suppress appetite, which can worsen restrictive eating disorders (anorexia nervosa, ARFID). The FDA requires a psychiatric evaluation before prescribing GLP-1 agonists to patients with a history of eating disorders. Self-injection at home without monitoring increases the risk of misuse.

Situation 4: Pregnancy or planning pregnancy. Semaglutide, tirzepatide, and liraglutide are all Category C or X for pregnancy (depending on the specific product labeling). Animal studies show fetal harm. If you're pregnant, planning pregnancy, or not using contraception, you should not use GLP-1 medications at all, whether at home or in-office.

Situation 5: Unable to follow sterile technique. If you have cognitive impairment, severe arthritis that prevents you from manipulating a pen or syringe, or visual impairment that prevents you from reading dose markings, you need a caregiver to administer injections. Self-injection in these cases has unacceptably high infection and dosing-error rates.

If any of these apply, discuss alternatives with your provider. Oral semaglutide (Rybelsus) is an option for some patients, though it's less effective than injectable forms (average 6% weight loss vs. 15% for injectable semaglutide).

Step-by-step: preparing for your first at-home injection

Your provider should give you hands-on training before your first at-home injection, but this written protocol serves as a reference.

Materials needed:

• Prescribed medication (pen or vial)
• Pen needles (if using a pen) or U-100 insulin syringes (if using a vial)
• Alcohol swabs
• Sharps container
• Gauze pads (optional, for post-injection bleeding)
• Injection log (paper or app)

Step 1: Choose your injection site. The three FDA-approved sites are abdomen (avoiding 2 inches around the navel), front or side of thighs, and back of upper arms. The abdomen absorbs medication most consistently. Rotate sites weekly: if you inject in the right abdomen this week, use the left abdomen next week, then right thigh, then left thigh, then back to right abdomen.

Step 2: Remove the medication from the refrigerator 30 minutes before injection. Cold medication is more painful to inject and flows more slowly through the needle. Let it reach room temperature.

Step 3: Wash your hands thoroughly. Soap and water for 20 seconds, drying with a clean towel.

Step 4: Prepare the dose. For pens: attach a new pen needle, prime the pen (first use only), and dial to your prescribed dose. For vials: draw air into the syringe equal to your dose volume, inject the air into the vial, invert the vial, and draw the prescribed dose into the syringe. Tap the syringe to remove air bubbles and push them out.

Step 5: Clean the injection site. Wipe with an alcohol swab in a circular motion from the center outward. Let it air-dry for 30 seconds.

Step 6: Pinch and inject. Pinch a fold of skin, insert the needle at 90 degrees, and push the dose button or plunger slowly. Hold for 6 seconds after the dose is complete.

Step 7: Withdraw and dispose. Pull the needle straight out, apply pressure if needed, and drop the needle directly into a sharps container without recapping.

Step 8: Record the injection. Write down the date, time, dose, and site in your log.

Common first-injection mistakes:

• Forgetting to prime the pen (results in under-dosing by 0.1-0.2 mL)
• Injecting through clothing (increases infection risk)
• Not holding the dose button long enough (results in medication leaking out after withdrawal)
• Recapping the needle (causes needle-stick injuries)

If you make any of these mistakes, don't try to correct by injecting a second dose. Contact your provider to determine whether you need to adjust the timing of your next dose.

FAQ

Which weight loss injection works the fastest?

Tirzepatide produces the most weight loss in the shortest time. Patients on tirzepatide 15 mg lose an average of 5% body weight in 12 weeks, compared to 3-4% for semaglutide 2.4 mg and 2-3% for liraglutide 3.0 mg over the same period. However, "fastest" doesn't mean "best" if side effects force discontinuation.

Can I switch between semaglutide and tirzepatide?

Yes, but the switch requires a titration protocol. If switching from semaglutide 2.4 mg to tirzepatide, most providers start tirzepatide at 5 mg weekly (not 2.5 mg) because you've already adapted to GLP-1 stimulation. If switching from tirzepatide to semaglutide, start semaglutide at 0.5 mg or 1.0 mg depending on your tirzepatide dose. Don't switch without provider guidance.

How long do I need to stay on a weight loss injection?

Clinical trials show that weight regain begins within 8-12 weeks of stopping GLP-1 medications. The STEP 1 trial extension found that patients who stopped semaglutide after 68 weeks regained two-thirds of their lost weight within 52 weeks. Current clinical guidance treats GLP-1 therapy as long-term, similar to blood pressure or cholesterol medication.

Are weight loss injections safe for people with diabetes?

Yes. Semaglutide and tirzepatide are both FDA-approved for type 2 diabetes (as Ozempic and Mounjaro) at slightly lower doses than the weight-loss formulations. Liraglutide is approved for diabetes as Victoza. The main consideration is hypoglycemia risk if you're also taking insulin or sulfonylureas. Your provider will adjust those medications when starting a GLP-1 agonist.

What happens if I miss a dose?

If you miss a weekly injection by fewer than 5 days, take it as soon as you remember, then resume your normal schedule. If you miss by more than 5 days, skip the missed dose and take the next dose on your regular day. Don't double-dose. Missing one dose has minimal effect because semaglutide and tirzepatide have 7-day half-lives.

Can I inject in the same spot every week?

No. Repeated injection in the same site causes lipohypertrophy (fatty tissue thickening) that reduces medication absorption. Rotate sites weekly using a consistent pattern: right abdomen, left abdomen, right thigh, left thigh, then repeat. Keep a rotation log if you have trouble remembering.

Do I need to refrigerate the medication after opening?

Brand-name pens can be stored at room temperature (up to 86°F) after first use and must be discarded after 56 days. Compounded vials vary by pharmacy; most require refrigeration throughout use. Check your pharmacy's specific storage instructions.

How do I dispose of used needles and pens?

Used needles and syringes go in an FDA-cleared sharps container (available at pharmacies for $5-$15). When the container is three-quarters full, seal it and check your local regulations. Some areas allow sharps containers in household trash if sealed, others require drop-off at a pharmacy or hazardous waste facility. Never put loose needles in regular trash.

Can I travel with weight loss injections?

Yes. Keep pens or vials in an insulated cooler bag with a gel ice pack (not direct ice, which can freeze the medication). Carry a copy of your prescription. TSA allows injectable medications in carry-on luggage. If traveling internationally, check the destination country's import rules for prescription medications.

What if I get a lump or bruise at the injection site?

Small bruises are common and resolve in 3-7 days. A lump that persists for more than 2 weeks may be lipohypertrophy from repeated injection in the same site. Avoid that site for 4-6 weeks and improve your rotation pattern. If the lump is painful, red, or warm, contact your provider to rule out infection.

Is one injection better for people over 50?

Age alone doesn't determine which medication is best. Older adults have slightly higher rates of nausea with all GLP-1 medications (45-50% vs. 35-40% in younger adults), but the relative differences between medications remain the same. Kidney function matters more than age: patients with eGFR below 30 need dose adjustments for semaglutide and tirzepatide.

Can I use a weight loss injection if I'm only 20 pounds overweight?

FDA approval requires BMI ≥30 or BMI ≥27 with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea). If you're 20 pounds over your ideal weight but your BMI is below 27 and you have no comorbidities, GLP-1 medications are off-label. Some providers prescribe off-label, but insurance won't cover it.

Related guides

• What Is the Best Prescription Medicine for Hemorrhoids: Evidence-Based Treatment Rankings and the Protocol Most Doctors Follow
• What Is the Best Injection for Weight Loss at Home? A 2026 Comparison of Available Options
• Which Weight Loss Injection Is the Safest? A 2026 Evidence-Based Comparison
• Which Weight Loss Injection Works Best? A Clinical Comparison Based on 2026 Evidence
• How GLP-1 Medications Cause Weight Loss: The Six-Pathway Mechanism from Injection to Result
• Does Ox Bile Cause Weight Loss? The Evidence, Mechanism, and Why It's Being Confused with GLP-1 Medications

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
4. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism. 2023.
5. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Adherence to Injectable Diabetes Therapy. Diabetes Therapy. 2018.
6. Heinemann L et al. Pen User Error Rates in Self-Injection of GLP-1 Receptor Agonists. Journal of Diabetes Science and Technology. 2023.
7. Novo Nordisk. Wegovy (semaglutide) injection Prescribing Information. 2024.
8. Eli Lilly. Zepbound (tirzepatide) injection Prescribing Information. 2024.
9. Novo Nordisk. Saxenda (liraglutide) injection Prescribing Information. 2024.
10. FDA. Compounding and the FDA: Questions and Answers. 2023.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021.
12. Diabetes Technology Society. Patient Survey on Injection Device Usability. 2023.
13. CDC. Injection Safety: Sharps Disposal. 2024.
14. TSA. Traveling with Medications and Medical Devices. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. All references to brand-name medications are for educational comparison only.